Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27611807 | 0.98 | SIGMAR1 (0.42) | SIGMAR1DRD2HTR2AKDM1ATRPM8 | |
| Maleic Acid SCHEMBL27593664 | 0.86 | TRPM8 (0.42) | SIGMAR1DRD2HTR2ATRPM8EPHX2 | |
| SCHEMBL23385889 | 0.80 | SIGMAR1 (0.40) | SIGMAR1DRD2HTR2AKDM1ATRPM8 | |
| SCHEMBL29736073 | 0.80 | SIGMAR1 (0.45) | SIGMAR1DRD2HTR2AKDM1ATRPM8 | |
| SCHEMBL23811463 | 0.80 | CYP2D6 (0.39) | HTR2AKDM1AMAOBMAOA | |
| SCHEMBL546544 | 0.80 | SIGMAR1 (0.45) | SIGMAR1DRD2HTR2AKDM1ATRPM8 | |
| SCHEMBL27471149 | 0.79 | HTR2B (0.42) | SIGMAR1KDM1ABACE1KCNH2MAOB | |
| Hydrochloric Acid SCHEMBL27471847 | 0.78 | SIGMAR1 (0.44) | SIGMAR1DRD2HTR2AKDM1ATRPM8 | |
| Ammonia Solution, Strong SCHEMBL29163352 | 0.78 | SIGMAR1 (0.44) | SIGMAR1DRD2HTR2AKDM1ATRPM8 | |
| SCHEMBL4152628 | 0.77 | SIGMAR1 (0.43) | SIGMAR1DRD2HTR2ATRPM8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100430391-C | Method for producing 2-[-5-(4-fluoprophenyl)-3-pyridylmethylaminomethyl]-chromane | MERCK PATENT GMBH (DE) | 2008-11-05 | — | — | CN | claimed |
| CN-1622944-A | Method for producing 2-[-5-(4-fluoprophenyl)-3-pyridylmethylaminomethyl]-chromane | MERCK PATENT GMBH (DE) | 2005-06-01 | — | — | CN | claimed |
| CN-100516066-C | Compounds for treating impaired fundic relaxation | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-22 | — | — | CN | disclosed |
| CN-100469368-C | Use of adatanserin for treating neurogenerative disorders | WHISCH CO (US) | 2009-03-18 | — | — | CN | disclosed |
| CN-100430391-C | Method for producing 2-[-5-(4-fluoprophenyl)-3-pyridylmethylaminomethyl]-chromane | MERCK PATENT GMBH (DE) | 2008-11-05 | — | — | CN | disclosed |
| CN-1288157-C | Dioxinopyridine compounds for the treatment of impaired fundic relaxation, process for their preparation and their use | JANSSEN PHARMACEUTICA NV (BE) | 2006-12-06 | — | — | CN | disclosed |
| CN-1781921-A | Compounds for treating impaired fundic relaxation | JANSSEN PHARMACEUTICA NV (BE) | 2006-06-07 | — | — | CN | disclosed |
| CN-1249044-C | Chromanone derivatives | MERCK PATENT GMBH (DE) | 2006-04-05 | — | — | CN | disclosed |
| CN-1622944-A | Method for producing 2-[-5-(4-fluoprophenyl)-3-pyridylmethylaminomethyl]-chromane | MERCK PATENT GMBH (DE) | 2005-06-01 | — | — | CN | disclosed |
| US-6900222-B1 | Pyrrolidinyl, piperdinyl or homopiperidinyl substituted (benzodioxan, benzofuran or benzopyran) derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-31 | — | — | US | disclosed |
| US-6747045-B2 | SUCH AS 1-(3-(((3,4-DIHYDRO-2H-1-BENZOPYRAN-2-YL)METHYL) AMINO)-PROPYL)TETRAHYDRO-2(1H)-PYRIMIDINONE FOR TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER GASTROINTESTINAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-08 | — | — | US | disclosed |
| CN-1390128-A | Use of adatanserin for the treatment of neurodegenerative diseases | WHISCH CO (US) | 2003-01-08 | — | — | CN | disclosed |
| CN-1086703-C | Crystalline hydrochloride of (R)-(-)2{N-4[4-(1,1-dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman | BAYER AG (DE) | 2002-06-26 | — | — | CN | disclosed |
| CN-1353708-A | Pyrrolidinyl-, piperidinyl-or homopiperidinyl-substituted (benzodioxan, benzofuran or benzopyran) derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2002-06-12 | — | — | CN | disclosed |
| US-6331561-B2 | ALZHEIMER'S AND PARKINSON DISEASE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-12-18 | — | — | US | disclosed |
| US-20010018530-A1 | Use of substituted amino-methyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration | FAHRIG THOMAS (DE) | 2001-08-30 | — | — | US | disclosed |
| CN-1152574-A | Crystalline hydrochloride of (R)-(-)2{N-4[4-(1,1-dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman | BAYER AG (DE) | 1997-06-25 | — | — | CN | disclosed |
| CN-1024667-C | process for preparing substituted aminomethyl tetralins and substituted aminomethyl hydrogenated benzopyrans and their salts | BAYER AG (DE) | 1994-05-25 | — | — | CN | disclosed |
| CN-1039809-A | The aminomethyl tetraline that replaces and the preparation of heterocycle homologue thereof | BAYER AG (DE) | 1990-02-21 | — | — | CN | disclosed |
| EP-0114374-B1 | SUBSTITUTED 4-AMINOMETHYLENE CHROMANS OR CHROMENES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINES | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018530-A1 | Use of substituted amino-methyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration | GAP43, DCX, CHAT | SIGMAR1 3367/4885DRD2 933/4885HTR2A 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.